Postoperative pathological complete response in a patient with PD‑L1‑negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment combined with chemotherapy: A case report and literature review

Cui,Guanghua; Qu,Di; Bai,Yun; Sun,Xiaoke; Li,Yingjue; Yang,Yu

doi:10.3892/ol.2023.13974

Postoperative pathological complete response in a patient with PD‑L1‑negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment combined with chemotherapy: A case report and literature review

Authors:
- Guanghua Cui
- Di Qu
- Yun Bai
- Xiaoke Sun
- Yingjue Li
- Yu Yang
View Affiliations

Affiliations: Department of Medical Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 1500811, P.R. China
Published online on: July 24, 2023 https://doi.org/10.3892/ol.2023.13974
Article Number: 388
Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The utilization of immune checkpoint inhibitors in oncological treatment has increased in recent years. The therapeutic strategy of targeting the programmed death‑1 (PD‑1)/programmed death‑ligand 1 (PD‑L1) pathway has altered the management of advanced non‑small cell lung carcinoma (NSCLC). Tislelizumab, a novel anti‑PD‑1 monoclonal antibody developed in China, has demonstrated efficacy in treating advanced NSCLC. However, its potential role as a neoadjuvant therapy for locally advanced NSCLC has not been definitively established. Current guidelines do not specify which patient populations may gain the most benefit from neoadjuvant immunotherapy coupled with chemotherapy, nor do they indicate the optimal timing, dose or duration of adjuvant maintenance therapy post‑NSCLC surgery. Similarly, data concerning the safety and practicability of surgical resection following neoadjuvant tislelizumab treatment for NSCLC remain limited. The present study describes the case of a patient diagnosed with stage IIIB NSCLC, which was initially deemed unresectable. A preoperative biopsy of the tumor mass revealed squamous cell carcinoma and a negative PD‑L1 gene test. Notably, after two cycles of neoadjuvant tislelizumab treatment coupled with chemotherapy, the tumor exhibited marked shrinkage. This permitted the patient to undergo thoracoscopic radical lung cancer resection, which resulted in a pathological complete response. Postoperative pathology identified a large infiltration of lymphoplasmacytic cells and foamy histiocytes. The patient experienced grade 2 myelosuppression, a condition that was successfully addressed with the administration of recombinant human granulocyte colony‑stimulating factor. The present case indicates the safety and feasibility of neoadjuvant immunotherapy integrated with chemotherapy for patients with locally advanced, PD‑L1‑negative NSCLC prior to surgical intervention. Moreover, the case suggests the potential of this therapeutic combination to alter the tumor microenvironment. However, the generalization of these findings necessitates further validation through randomized multicenter trials.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
3	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, et al: NCCN guidelines insights: Non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 19:254–266. 2021. View Article : Google Scholar : PubMed/NCBI
4	NSCLC Meta-analyses Collaborative Group, . Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, et al: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 375:1267–1277. 2010. View Article : Google Scholar : PubMed/NCBI
5	NSCLC Meta-analysis Collaborative Group, : Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data. Lancet. 383:1561–1571. 2014. View Article : Google Scholar : PubMed/NCBI
6	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar : PubMed/NCBI
7	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
8	Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, et al: Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: The MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 6:661–674. 2020. View Article : Google Scholar : PubMed/NCBI
9	Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, et al: Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 378:1976–1986. 2018. View Article : Google Scholar : PubMed/NCBI
10	Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, et al: Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 21:1413–1422. 2020. View Article : Google Scholar : PubMed/NCBI
11	Eichhorn F, Klotz LV, Kriegsmann M, Bischoff H, Schneider MA, Muley T, Kriegsmann K, Haberkorn U, Heussel CP, Savai R, et al: Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. Lung Cancer. 153:150–157. 2021. View Article : Google Scholar : PubMed/NCBI
12	Tong BC, Gu L, Wang X, Wigle DA, Phillips JD, Harpole DH Jr, Klapper JA, Sporn T, Ready NE and D'Amico TA: Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 163:427–436. 2022. View Article : Google Scholar : PubMed/NCBI
13	Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, et al: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019. View Article : Google Scholar : PubMed/NCBI
14	Schuchert MJ, Normolle DP, Awais O, Pennathur A, Wilson DO, Luketich JD and Landreneau RJ: Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer. Lung Cancer. 128:145–151. 2019. View Article : Google Scholar : PubMed/NCBI
15	Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, et al: Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial. Nat Med. 27:504–514. 2021. View Article : Google Scholar : PubMed/NCBI
16	William WN Jr, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, et al: Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 8:222–228. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W, Zhang Y, Zhou X, Wang Z, Wang Y, et al: The binding of an anti-PD-1 antibody to FcγRI has a profound impact on its biological functions. Cancer Immunol Immunother. 67:1079–1090. 2018. View Article : Google Scholar : PubMed/NCBI
18	Lee A and Keam SJ: Tislelizumab: First approval. Drugs. 80:617–624. 2020. View Article : Google Scholar : PubMed/NCBI
19	Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma Z, Li X, Zhuang W, Liu Y, et al: Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): A randomized phase 3 trial. J Thorac Oncol. 16:1512–1522. 2021. View Article : Google Scholar : PubMed/NCBI
20	Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, et al: Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A phase 3 randomized clinical trial. JAMA Oncol. 7:709–717. 2021. View Article : Google Scholar : PubMed/NCBI
21	Kutob L and Schneider F: Lung cancer staging. Surg Pathol Clin. 13:57–71. 2020. View Article : Google Scholar : PubMed/NCBI
22	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI
23	Wang J, Shen Q, Shi Q, Yu B, Wang X, Cheng K, Lu G and Zhou X: Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry. J Exp Clin Cancer Res. 33:1092014. View Article : Google Scholar : PubMed/NCBI
24	Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA and Stratton MR: The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet Chapter 10. Unit 10.11. 2008. View Article : Google Scholar : PubMed/NCBI
25	Lei Y, Lei Y, Shi X and Wang J: EML4-ALK fusion gene in non-small cell lung cancer. Oncol Lett. 24:2772022. View Article : Google Scholar : PubMed/NCBI
26	Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, et al: Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W. J Clin Oncol. 38:2407–2417. 2020. View Article : Google Scholar : PubMed/NCBI
27	Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE and Hammerman PS: Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. 8:1434–1437. 2013. View Article : Google Scholar : PubMed/NCBI
28	Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, et al: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial. Lancet Oncol. 16:763–774. 2015. View Article : Google Scholar : PubMed/NCBI
29	Topalian SL, Taube JM and Pardoll DM: Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 367:eaax01822020. View Article : Google Scholar : PubMed/NCBI
30	Broderick SR and Bott MJ: Neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 158:1471–1474. 2019. View Article : Google Scholar : PubMed/NCBI
31	Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH, et al: Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 169:750–765.e17. 2017. View Article : Google Scholar : PubMed/NCBI
32	Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
33	Williams PA, Zaidi SK and Sengupta R: AACR report on the impact of COVID-19 on cancer research and patient care. Clin Cancer Res. 28:609–610. 2022. View Article : Google Scholar : PubMed/NCBI
34	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, et al: NCCN guidelines^® insights: Non-small cell lung cancer, version 2.2023. J Natl Compr Canc Netw. 21:340–350. 2023. View Article : Google Scholar : PubMed/NCBI
35	Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Péchoux C, Pirker R, Pinel MI, et al: Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 28:35–42. 2010. View Article : Google Scholar : PubMed/NCBI
36	Wang J, Yu X, Lu S, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, et al: Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC). J Clin Oncol. 38 (Suppl):S95542020. View Article : Google Scholar
37	BeiGene, . Comparing the efficacy and safety of a new additional treatment with tislelizumab in non-small cell lung cancer (NSCLC). U.S. National Library of Medicine; 2023, Available from:. https://clinicaltrials.gov/ct2/show/NCT04379635
38	Hu X, Hu C, Liu X, Ma F, Xie J, Zhong P, Tang C, Fan D, Gao Y, Feng X, et al: Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel-based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Front Oncol. 12:10576462023. View Article : Google Scholar : PubMed/NCBI
39	La Fleur L, Falk-Sörqvist E, Smeds P, Berglund A, Sundström M, Mattsson JS, Brandén E, Koyi H, Isaksson J, Brunnström H, et al: Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer. 130:50–58. 2019. View Article : Google Scholar : PubMed/NCBI
40	Travis WD, Dacic S, Sholl LM and Wistuba II: Pathologic assessment of lung squamous cell carcinoma after neoadjuvant immunotherapy. J Thorac Oncol. 16:e9–e10. 2021. View Article : Google Scholar : PubMed/NCBI
41	Szeto GL and Finley SD: Integrative approaches to cancer immunotherapy. Trends Cancer. 5:400–410. 2019. View Article : Google Scholar : PubMed/NCBI
42	Hu J, Zhang L, Xia H, Yan Y, Zhu X, Sun F, Sun L, Li S, Li D, Wang J, et al: Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med. 15:142023. View Article : Google Scholar : PubMed/NCBI
43	Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI
44	Bott MJ, Yang SC, Park BJ, Adusumilli PS, Rusch VW, Isbell JM, Downey RJ, Brahmer JR, Battafarano R, Bush E, et al: Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 158:269–276. 2019. View Article : Google Scholar : PubMed/NCBI
45	Lee J, Chaft J, Nicholas A, Patterson G, Waqar S, Toloza E, Haura E, Raz D, Reckamp K, Merritt R, et al: P2.04–88 surgical outcomes of a multicenter phase II trial of neoadjuvant atezolizumab in resectable stages Ib-IIIb NSCLC: Update on LCMC3 clinical trial. J Thorac Oncol. 14 (Suppl):S7442019. View Article : Google Scholar
46	Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, et al: Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 15:816–826. 2020. View Article : Google Scholar : PubMed/NCBI
47	Sun C, Liu Y, Zhang P, Wang X, Xu Y, Lin X, Ma X, Guo Y, Qiu S, Shao G, et al: Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: A single-arm, phase 2 trial. J Cancer Res Clin Oncol. 149:819–831. 2023. View Article : Google Scholar : PubMed/NCBI
48	Provencio-Pulla M, Nadal-Alforja E, Cobo M, Insa A, Costa Rivas M, Majem M, Rodriguez-Abreu D, Lopez-Vivanco G, Domine M, Del Barco Morillo E, et al: Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study-NADIM study-SLCG. J Clin Oncol. 36 (Suppl):S85212018. View Article : Google Scholar
49	Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, Garofano RF, Stoopler MB, Cheng SK, White A, et al: Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 21:786–795. 2020. View Article : Google Scholar : PubMed/NCBI
50	Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer. Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI